Key terms
About INO
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest INO news
Mar 28
3:35pm ET
Inovio Pharmaceuticals: A Strong Buy on Promising IL-12 Therapy Developments and Market Interest
Mar 07
10:05am ET
Inovio Pharmaceuticals: A Strong Buy on Robust Clinical Progress and Financial Health
Mar 07
6:28am ET
Inovio Pharmaceuticals: Hold Rating with Promising Pipeline Despite Financial Losses
Mar 06
4:12pm ET
Inovio expects cash runway to extend into 2Q25
Mar 06
4:08pm ET
Inovio expects cash runway to extend into 2H25
Mar 06
4:07pm ET
Inovio reports Q4 EPS ($1.10), consensus ($1.27)
Mar 06
3:11pm ET
Inovio options imply 15.7% move in share price post-earnings
Mar 06
7:05am ET
Options Volatility and Implied Earnings Moves Today, March 06, 2024
Mar 05
8:47pm ET
RBC Capital Sticks to Their Hold Rating for Inovio Pharmaceuticals (INO)
Jan 26
4:24am ET
Inovio Pharmaceuticals Announces 1-for-12 Reverse Stock Split
Jan 25
9:49am ET
Tesla, Boeing downgraded: Wall Street’s top analyst calls
Jan 25
9:49am ET
Tesla, Boeing downgraded: Wall Street’s top analyst calls
Jan 25
8:10am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jan 25
7:36am ET
Oppenheimer upgrades Inovio to Outperform on INO-3107 potential
Jan 25
7:01am ET
Inovio upgraded to Outperform from Perform at Oppenheimer
Jan 24
7:50pm ET
Inovio trading halted, news pending
Jan 23
8:09am ET
Inovio announces effective date of 1-for-12 reverse stock split
Jan 04
8:07am ET
Inovio, Coherus Biosciences announces clinical collaboration
Jan 04
4:39am ET
Inovio initiated with an Outperform at JMP Securities
Jan 04
12:25am ET
Inovio Pharmaceuticals: A Strong Buy on Accelerated Approval Prospects for INO-3107
Jan 03
12:20pm ET
Analysts Conflicted on These Healthcare Names: Avenue Therapeutics (ATXI) and Inovio Pharmaceuticals (INO)
Jan 03
8:07am ET
Inovio to submit BLA for INO-3107 in 2H24
No recent press releases are available for INO
INO Financials
Key terms
Ad Feedback
INO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
INO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
